Tag: Blood Cancer Drug
AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More
Cyclacel’s blood cancer drug for elderly patients, sapacitabine fails in phase 3 trial
The blood cancer drug for elderly patients, sapacitabine (CYC682) developed by New Jersey based Cyclacel Pharmaceuticals has failed to meet its objective in a crucial ... Read More
Pfizer’s blood cancer drug inotuzumab ozogamicin gets FDA priority review
Pfizer’s blood cancer drug, inotuzumab ozogamicin has secured a priority review designation from the US Food and Drug Administration (FDA). Inotuzumab ozogamicin has been developed ... Read More